Business Standard

Bayer launches novel heart failure drug Verquvo for Rs 127 a pill

In India there are between 8-10 million people with heart failure, making it one of the world's largest populations with the malady

bayer
Premium

The drug named Verquvo (vericiguat) is the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalizations among worsening heart failure patients, the company said.

Sohini Das Mumbai
Bayer launched a novel heart failure drug  in India that it has co-developed with Merck at one-fifteenth of the global price at Rs 127 per pill. It’s a one pill a day therapy.

The drug named Verquvo (vericiguat) is the first novel treatment approved to reduce the risk of cardiovascular deaths and repeated hospitalisation among worsening heart failure patients, the company said. 

In India there are between 8-10 million people with heart failure, making it one of the world's largest populations with the malady. At 55-60 years, Indian patients are also a decade younger than their western counterparts. Despite the

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 27 2022 | 6:37 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com